Open AccessmiRNA in prostate cancer: challenges toward translation
Author(s) -
Irena Abramović,
Monika Ulamec,
Ana Katušić Bojanac,
Floriana Bulić-Jakuš,
Davor Ježek,
Nino Sinčić
Publication year - 2020
Publication title -
epigenomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.265
H-Index - 60
eISSN - 1750-1911
pISSN - 1750-192X
DOI - 10.2217/epi-2019-0275
Subject(s) - prostate cancer , microrna , clinical practice , biology , cancer , translation (biology) , computational biology , reliability (semiconductor) , bioinformatics , oncology , medicine , genetics , messenger rna , power (physics) , physics , family medicine , quantum mechanics , gene
Prostate cancer (PCa) represents the most commonly diagnosed neoplasm among men. miRNAs, as biomarkers, could further improve reliability in distinguishing malignant versus nonmalignant, and aggressive versus nonaggressive PCa. However, conflicting data was reported for certain miRNAs, and there was a lack of consistency and reproducibility, which has been attributed to diverse (pre)analytical factors. In order to address current challenges in miRNA clinical research on PCa, a PubMed-based literature search was conducted with the last update in May 2019. After identifying critical variations in designs and protocols that undermined clear-cut evidence acquisition, and reliable translation into clinical practice, we propose guidelines for most critical steps that should be considered in future research of miRNA as biomarkers, especially in PCa.